FDA approves Vyalev for advanced Parkinson's disease
The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...
HealthDay on MSN1d
FDA Approves Vyalev for Advanced Parkinson Disease
The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...
Spokane woman gets back her 'normal life' from newly approved Parkinson's disease treatment
After being diagnosed with Parkinson's disease at 50, Janice Hall felt her tremors get worse. Three years after being diagnosed she could "feel a kind of fluttering" that her medication could not stop ...
GlobalData on MSN6d
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
The US FDA has approved AbbVie's VYALEV to treat motor fluctuations in adults with advanced Parkinson's disease (PD).
FiercePharma6d
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...
pharmaphorum6d
AbbVie gets continuous Parkinson's drug over the line in US
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...
AbbVie’s Vyalev approved by FDA in advanced Parkinson’s disease
AbbVie announced that the FDA has approved Vyalev as the first and only subcutaneous 24-hour infusion of levodopa-based ...
BioPharma Dive6d
After rejections, AbbVie secures approval for Parkinson’s drug
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
Zacks.com on MSN5d
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy ...
Injectable drug to ease advanced Parkinson's disease symptoms approved by FDA
The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
McKnight's Long-Term Care News4d
A new treatment option gets FDA approval for adults with advanced Parkinson’s disease
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...